Quince Therapeutics (NASDAQ:QNCX) Receives “Buy” Rating from D. Boral Capital

D. Boral Capital restated their buy rating on shares of Quince Therapeutics (NASDAQ:QNCX) in a research report released on Wednesday,Benzinga reports. D. Boral Capital currently has a $12.00 price target on the stock.

Several other brokerages have also recently issued reports on QNCX. RODMAN&RENSHAW upgraded shares of Quince Therapeutics to a “strong-buy” rating in a report on Tuesday, October 29th. EF Hutton Acquisition Co. I upgraded shares of Quince Therapeutics to a “strong-buy” rating in a research note on Tuesday, October 22nd. Brookline Capital Management began coverage on shares of Quince Therapeutics in a research note on Wednesday, December 18th. They issued a “buy” rating and a $9.00 price objective for the company. Rodman & Renshaw initiated coverage on Quince Therapeutics in a research report on Tuesday, October 29th. They set a “buy” rating and a $11.00 target price on the stock. Finally, Maxim Group started coverage on Quince Therapeutics in a report on Thursday, November 7th. They issued a “buy” rating and a $6.00 price target on the stock. Four equities research analysts have rated the stock with a buy rating and two have issued a strong buy rating to the stock. Based on data from MarketBeat.com, Quince Therapeutics has an average rating of “Buy” and a consensus price target of $9.50.

Quince Therapeutics Price Performance

Shares of QNCX stock opened at $1.67 on Wednesday. The stock has a market capitalization of $73.48 million, a price-to-earnings ratio of -1.35 and a beta of 0.61. The company has a current ratio of 9.53, a quick ratio of 9.53 and a debt-to-equity ratio of 0.33. Quince Therapeutics has a twelve month low of $0.51 and a twelve month high of $2.45. The stock has a fifty day simple moving average of $1.81 and a two-hundred day simple moving average of $1.26.

Hedge Funds Weigh In On Quince Therapeutics

A number of large investors have recently made changes to their positions in QNCX. Anfield Capital Management LLC purchased a new position in Quince Therapeutics during the 4th quarter worth $50,000. Geode Capital Management LLC boosted its holdings in Quince Therapeutics by 24.2% in the third quarter. Geode Capital Management LLC now owns 339,125 shares of the company’s stock worth $263,000 after acquiring an additional 66,170 shares in the last quarter. Finally, Scharf Investments LLC purchased a new stake in shares of Quince Therapeutics during the fourth quarter worth about $170,000. 30.75% of the stock is owned by institutional investors and hedge funds.

About Quince Therapeutics

Quince Therapeutics, Inc, a biopharmaceutical company, focuses on acquiring, developing, and commercializing therapeutics for patients with debilitating and rare diseases. The company's lead asset candidature comprises EryDex for the treatment of rare pediatric neurodegenerative disease, including A-T, an inherited autosomal recessive neurodegenerative and immunodeficiency disorder caused by mutations in ATM gene.